Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
generic:
brand:
classes:
[[:Category:Antihypertensives|Antihypertensive]] (22) ·
[[:Category:Lipid-lowering_agents|Lipid-lowering agent]] (10) ·
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (7) ·
[[:Category:Analgesics|Analgesic]] (6) ·
[[:Category:Antianginals|Antianginal]] (6) ·
[[:Category:Beta-lactam_antibiotics|β-lactam antibiotic]] (6) ·
[[:Category:Corticosteroids|Corticosteroid]] (6) ·
[[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]] (5) ·
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (5) ·
[[:Category:Immunosuppressants|Immunosuppressant]] (5) ·
[[:Category:Statins|Statin]] (5) ·
[[:Category:ACE_inhibitors|ACE inhibitor]] (4) ·
[[:Category:Glaucoma_medications|Glaucoma medication]] (4) ·
[[:Category:Insulins|Insulin]] (4) ·
[[:Category:Ocular_hypotensive_agents|Ocular hypotensive agent]] (4)
mechanism:
uses:
'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' (5) ·
'"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"' (3) ·
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (3) ·
'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"' (2)
starting dose:
preparations:
fda max:
routes:
Oral (99) ·
IV (29) ·
IM (12) ·
Topical (11) ·
Subcutaneous (5) ·
intranasal (4) ·
ophthalmic (4) ·
Topical ophthalmic (4) ·
vaginal (4) ·
rectal (3) ·
transdermal (3) ·
Inhaled (MDI (2) ·
intra-articular (2) ·
intramuscular (2) ·
intravenous (2) ·
intravitreal (2) ·
nebulized) (2) ·
Subcutaneous (never IV; not for use in insulin pumps) (2)
onset:
Hours (10) ·
1-2 hours (3) ·
LDL lowering at 2 weeks, max by 4 weeks (3) ·
30-60 minutes (2) ·
BP and symptomatic LUTS improvement within 1-2 weeks (2) ·
BP effect within 1-2 weeks (2) ·
Clinical improvement within 24-72 hours (2) ·
Motor improvement over days at therapeutic dose (2) ·
Postprandial glucose effect within days; HbA1c by 12 weeks (2)
duration:
halflife:
bioavailability:
pregnancy:
None (10) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (7) ·
Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (3) ·
Avoid in second and third trimesters; fetal SGLT2 inhibition disrupts kidney development.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Avoid where possible; class concerns as for other loop diuretics.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Generally considered safe (minimal systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Generally considered safe in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Generally considered safe; widely used.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Limited data; weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Limited human data; rarely indicated in pregnancy given the patient population.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Limited human data; β-blocker class effects include fetal growth restriction and neonatal bradycardia/hypoglycemia.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2)
Showing below up to 128 results in range #1 to #128.
A
- Acyclovir
- Albuterol
- Alendronate
- Allopurinol
- Amlodipine
- Amoxicillin
- Anastrozole
- Apixaban
- Atenolol
- Atorvastatin
- Azithromycin
B
C
- Calcitriol
- Carbamazepine
- Carvedilol
- Cefdinir
- Cefuroxime
- Celecoxib
- Cephalexin
- Chlorthalidone
- Ciclopirox
- Clobetasol
- Clopidogrel
- Colchicine
- Cyproheptadine
D
- Dapagliflozin
- Desiccated thyroid
- Dexamethasone
- Dicyclomine
- Diltiazem
- Donepezil
- Dorzolamide
- Doxazosin
- Doxycycline
- Dutasteride
E
F
G
H
I
- Icosapent Ethyl
- Indomethacin
- Insulin Aspart
- Insulin Degludec
- Insulin Detemir
- Insulin Glargine
- Ipratropium
- Irbesartan
- Isosorbide
K
L
- Labetalol
- Lactated Ringer's solution
- Lactulose
- Latanoprost
- Levothyroxine
- Linagliptin
- Liothyronine
- Lisinopril
- Losartan
- Lovastatin

